PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28286228-0	2017	The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells.	birinapant	17-27	diablo, IAP-binding mitochondrial protein	Mus musculus	4-8	
33080008-1	2020	The specific targeting of inhibitor of apoptosis (IAP) proteins by Smac-mimetic (SM) drugs, such as birinapant, has been tested in clinical trials of acute myeloid leukemia (AML) and certain solid cancers.	birinapant	100-110	diablo, IAP-binding mitochondrial protein	Mus musculus	67-71	
31032587-0	2018	[Anti-hepatoma effects of Smac analogue Birinapant and its related molecular mechanism].	birinapant	40-50	diablo, IAP-binding mitochondrial protein	Mus musculus	26-30	
27194728-3	2016	Potent ex vivo activity of the SMAC mimetic (SM) birinapant correlated with marked in vivo antileukemic effects, as indicated by delayed engraftment, decreased leukemia burden, and prolonged survival of xenografted mice.	birinapant	49-59	diablo, IAP-binding mitochondrial protein	Mus musculus	31-35	
25431358-3	2015	We investigated the effects of birinapant, a novel, second mitochondria-derived activator of caspases (SMAC)-mimetic that targets inhibitor of apoptosis proteins, alone and in combination with TNFalpha, TRAIL, or chemotherapy docetaxel.	birinapant	31-41	diablo, IAP-binding mitochondrial protein	Mus musculus	103-107